Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 47


Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings.

Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, Delaporte E, Messou E, McIntyre J, El Filali KM, Schechter M, Kumarasamy N, Bangsberg D, McPhail P, Van Der Borght S, Zala C, Egger M, Thiébaut R, Dabis F; T-LINC of IeDEA Collaboration (Asia, South America, East, Southern and West Africa).

BMC Infect Dis. 2012 Jun 28;12:147. doi: 10.1186/1471-2334-12-147.


Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.

Zala C, St Clair M, Dudas K, Kim J, Lou Y, White S, Piscitelli S, Dumont E, Pietropaolo K, Zhou XJ, Mayers D.

Antimicrob Agents Chemother. 2012 May;56(5):2570-5. doi: 10.1128/AAC.05597-11. Epub 2012 Feb 6.


A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial.

Burns KE, Chant C, Smith O, Cuthbertson B, Fowler R, Cook DJ, Kruger P, Webb S, Alhashemi J, Dominguez-Cherit G, Zala C, Rubenfeld GD, Marshall JC.

Trials. 2011 Mar 9;12:70. doi: 10.1186/1745-6215-12-70.


Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.

Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, Carcamo C, Cure-Bolt N, L'Italien GP, Mantilla P, Deibis L, Zala C, Suffert T.

Braz J Infect Dis. 2010 Mar-Apr;14(2):158-66.


Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.

Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF.

Antivir Ther. 2010;15(2):185-92. doi: 10.3851/IMP1514.


Respiratory disease in adults during pandemic (H1N1) 2009 outbreak, Argentina.

Zala C, Gonzalez R.

Emerg Infect Dis. 2009 Dec;15(12):2060-1. doi: 10.3201/eid1512.091062. No abstract available.


Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.

Murphy RL, Berzins B, Zala C, Fichtenbaum C, Dube MP, Guaraldi G, Torriani F, Belsey E, Mitchell C, Stein JH; SABAR Study Team.

AIDS. 2010 Mar 27;24(6):885-90. doi: 10.1097/QAD.0b013e3283352ed5.


A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.

Harris M, Côté H, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B, Singer J, Montaner J; CTN 177 Study Team.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):335-7. doi: 10.1097/QAI.0b013e3181938fc9. No abstract available.


Lack of viral selection in human immunodeficiency virus type 1 mother-to-child transmission with primary infection during late pregnancy and/or breastfeeding.

Ceballos A, Andreani G, Ripamonti C, Dilernia D, Mendez R, Rabinovich RD, Cárdenas PC, Zala C, Cahn P, Scarlatti G, Martínez Peralta L.

J Gen Virol. 2008 Nov;89(Pt 11):2773-82. doi: 10.1099/vir.0.83697-0.


Determinants of treatment access in a population-based cohort of HIV-positive men and women living in Argentina.

Zala C, Rustad CA, Chan K, Khan NI, Beltran M, Warley E, Ceriotto M, Druyts EF, Hogg RS, Montaner J, Cahn P; PUMA Study Group.

Medscape J Med. 2008 Apr 2;10(4):78.


Laboratory abnormalities among HIV-1-infected pregnant women receiving antiretrovirals in Latin America and the Caribbean.

Ceriotto M, Harris DR, Duarte G, Gonin R, Aguiar RP, Warley EM, Madi JM, Zala CA, Read JS; NICHD International Site Development Initiative (NISDI) Perinatal Study Group.

AIDS Patient Care STDS. 2008 Mar;22(3):167-71. doi: 10.1089/apc.2007.0080. No abstract available.


Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina.

Zala C, Rustad CA, Chan K, Khan NI, Beltran M, Warley E, Ceriotto M, Druyts EF, Hogg RS, Montaner J, Cahn P; PUMA Study Group.

J Int AIDS Soc. 2008 Apr 2;10(4):78. doi: 10.1186/1758-2652-10-4-78.


Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/microL: a randomized trial.

Krolewiecki AJ, Zala C, Vanzulli C, Pérez H, Iannella Mdel C, Bouzas MB, Gun A, Valiente J, Cassetti I, Cahn P.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):425-9.


Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.

Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, Hogg RS, Montaner JS.

J Infect Dis. 2006 Jan 15;193(2):259-68. Epub 2005 Dec 7.


Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C; BMS AI424-043 Study Group.

Curr Med Res Opin. 2005 Oct;21(10):1683-92.


Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.

Zala C, Alexander CS, Ochoa C, Guillemi S, Ting LS, Bonner S, Cahn P, Harrigan PR, Montaner JS.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):363-4. No abstract available.


Cytomegalovirus UL97 mutations associated with ganciclovir resistance in immunocompromised patients from Argentina.

Sánchez Puch S, Ochoa C, Carballal G, Zala C, Cahn P, Brunet R, Salomón H, Videla C.

J Clin Virol. 2004 Jul;30(3):271-5.


Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.

Martinez-Picado J, Negredo E, Ruiz L, Shintani A, Fumaz CR, Zala C, Domingo P, Vilaró J, Llibre JM, Viciana P, Hertogs K, Boucher C, D'Aquila RT, Clotet B; SWATCH Study Team.

Ann Intern Med. 2003 Jul 15;139(2):81-9.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk